	Substitute Form PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office		Attorney's Docket No. 06275-0150003	Application No. 10/010,283
	Information Disclosure Statement by Applicant		Applicant Carl-Axel Bauer et al.	
(Use several sheets if necessary)		Filing Date	Group Art Unit	
	(37 CFR §1.98(b))		November 13, 2001	1617

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	. 1	5,684,199	11/04/1997	Francotte			

	Foreign Patent Documents or Published Foreign Patent Applications							
Examiner	Desig.	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Trans Yes	lation No
Initial	ID	Number	Date	Patent Office	Class	Subciass	res	NO
	2	9703407-8	09/23/1998	Sweden				
	3	WO 92/11280	07/09/1992	WIPO				
	4	WO 98/15280	04/16/1998	WIPO				
	5	EP1085877	12/16/1999	Europe				
	6	WO 99/64014	12/16/1999	WIPO				
	7	EP0613371	03/06/2002	Europe				

	Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner Desig.				
Initial	ID D	Document		
	8	Ankerst et al., "Tolerability of a High Dose of Budesonide/Formoterol in a Single Inhaler in Patients with Asthma," manuscript (24 pages), as submitted for publication to Pulm. Pharm. Ther. with letter dated February 6, 2003 to the EPO, later published as Vol. 16(3), pages 147-151 (2003).		
	9	Ankerst et al., "Tolerability of a High Dose of Budesonide/Formoterol in a Single Inhaler in Patients with Asthma," Pulm. Pharm. Ther. Vol. 16(3):147-151 (2003) (abstract only).		
	10	Bjermer et al., "Long-acting β2-agonists: how they are used in an optimal way?," Respiratory Medicine, Vol. 91, pages 587-591 (1997).		
	11	Clinical Practice Guidelines, Expert Panel Report 2, Guidelines for the Diagnosis and Management of Asthma, NIH Publication No. 97-4051, July 1997.		
	12	Haughney et al., "Adjustable maintenance treatment with budesonide/formoterol combination rapidly improves and maintains quality of life in asthma patients," European Respiratory Society Annual Congress (ERS) Stockholm, September 14-18, 2002, Poster Presentation, P379, submitted to EPO with letter dated February 6, 2003.		
	13	Ind et al., "Managed Adjustable closing of budesonide/formoterol combination provides equivalent asthma control to fixed dosing at a lower overall dose," European Respiratory Society Annual Congress (ERS) Stockholm, September 14-18, 2002, Poster Presentation, P2450, submitted to EPO with letter dated February 6, 2003.		
	14	Letter from AstraZeneca to EPO dated 6 February 2003 in EP Application 99930103.9.		
	15	Lipworth, "A Single High Dose of Budesonide Rapidly Reverses Bronchoprotective Subsensitivity and B2-Adrencepter Down-Regulation in Patients Receiving Regular Formoterol," J. Allergy Clin. Immunol., Page S152, Section 629, January 1998.		

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through ci next communication to applicant.	itation if not in conformance and not considered. Include copy of this form with Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-0150003	Application No. 10/010,283
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Carl-Axel Bauer et al.	
		Filing Date November 13, 2001	Group Art Unit 1617

Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner	Desig.			
Initial	ID	Document		
	16	Lipworth, "Airway Subsensitivity with Long-Acting β2-Agonists," Drug Safety, Vol. 16(5), pages 295-308 (1997).		
	17	Lipworth et al., "Effects of Treatment with Formoterol on Bronchoprotection against Methacholine," Amer. J. Med., Vol. 104, pages 431-438 (1998).		
	18	Lôfdahl C.G. et al., "Long-acting \(\textit{\beta}\)2-adrenoceptor agonists: a new perspective in the treatment of asthma". The European Respiratory Journal, Vol. 4, pages 218-226 (1991).		
	19	O'Byrme et al., "Additive Effects of Budesonide and Formoterol in Reducing Severe Asthma Exacerbations over 12 Months," abstract of presentation given at the June 1-5, 1997, Annual Meeting of Allergology and Clinical Immunology, published as abstract 266 in Allergy 52, Supp. 37-89 (1997).		
	20	Olsson et al., "Adjustable maintenance treatment of asthma with budesonide and formoterol in a single inhaler," European Respiratory Society Annual Congress (ERS) Stockholm, September 14- 18, 2002, Poster Presentation, P2451, submitted to EPO with letter dated February 6, 2004.		
	21	Price et al., "Budesonide/formoterol with an adjustable maintenance plan costs less and is as effective as fixed dosing," European Respiratory Society Annual Congress (ERS) Stockholm, September 14-18, 2002, Poster Presentation, P2452, submitted to EPO with letter dated February 6, 2003.		
	22	Rosenhall et al., "Efficacy, safety and cost of budesonide/formoterol in a single inhaler compared with budeonside plus formoterol as separate inhalers", European Respiratory Society Annual Congress (ERS) Stockholm, September 14-18, 2002, Poster Presentation, P388, submitted to EPO with letter dated February 6, 2003.		
	23	Scrip, The Dialog Corporation, 1562, page 21 (31 October 1990).		
	24	Sung et al., "Randomized, Controlled Trial of Inhaled Budesonide as an Adjunct to Oral Prednisone in Acute Asthma," Academic Emergency Medicine, Vol. 5(3), pages 209-212 (1998).		
	25	Decision of the EPO Opposition Division regarding patent EP-B-1210943, dated December 5, 2008.		
	26	Statement of Grounds of Opposition to patent EP1085877 by Vectura Limited, received at the EPO on December 17, 2008.		
	27	Statement of Grounds of Opposition to patent EP1085877by Generics Limited, received at the EPO on December 19, 2008.		
	28	Statement of Grounds of Opposition to patent EP1085877 by Norton Health Care Limited, received at the EPO on December 19, 2008		
	29	Statement of Grounds of Opposition to patent EP1085877 by Ratiopharm GmbH, received at the EPO on December 17, 2008, translation attached.		
	30	"What You Should Know About Symbicort Turbohaler?, AstraZeneca, May 2001, 4 pages.		
	31	U.S. Examiner Rebecca Cook, USPTO Office Action in U.S. Serial No. 09/194,290, mailed August 16, 1999 (Rescinded) (5 pages)		
	32	U.S. Examiner Rebecca Cook, USPTO Office Action in U.S. Serial No. 09/194,290, mailed March 27, 2000 (case abandoned October 2, 2000) (6 pages)		
	33	U.S. Examiner Rebecca Cook, USPTO Office Action in U.S. Serial No. 09/670,457, mailed May 10, 2001 (case abandoned November 30, 2001) (6 pages)		
	34	U.S. Examiner Jennifer M. Kim, USPTO Office Action in U.S. Serial No. 09/367,950, mailed December 18, 2000 (9 pages)		
Examiner Sign	nature	Date Considered		

EXAMINER: Initials citation considered, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 U.S. Department of Commerce (Modified) Patent and Trademark Office		Attorney's Docket No. 06275-0150003	Application No. 10/010,283
	closure Statement oplicant	Applicant Carl-Axel Bauer et al.	
(Use several sheets if necessary)		Filing Date	Group Art Unit
(37 CFR \$1.98(b))		November 13, 2001	1617

	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner	Desig.	
Initial	ID	Document
	35	Fish & Richardson P.C., Amendment in Reply to Office Action dated December 18, 2001, in U.S.
		Serial No. 09/367,950, filed April 18, 2001 (8 pages)
	36	U.S. Examiner Jennifer M. Kim, USPTO Final Office Action in U.S. Serial No. 09/367,950, mailed May 21, 2001 (8 pages)
	37	Fish & Richardson P.C., Response to Final Office Action dated May 21, 2001, in U.S. Serial No. 09/367,950, filed August 21, 2001 (4 pages)
	38	U.S. Examiner Jennifer M. Kim, USPTO Office Action in U.S. Serial No. 09/367,950, mailed
	- 50	September 25, 2001 (8 pages)
	39	Fish & Richardson P.C., Response to Office Action dated May 21, 2001, in U.S. Serial No. 09/367,950, filed December 26, 2001 (3 pages)
	40	U.S. Examiner Jennifer M. Kim, USPTO Final Office Action in U.S. Serial No. 09/367,950, mailed
l		April 15, 2002 (6 pages)
	41	U.S. Examiner Jennifer M. Kim, in U.S. Serial No. 09/369,950, Interview Summary dated September 17, 2002 (1 page)
		Fish & Richardson P.C., Notice of Appeal in U.S. Serial No. 09/367,950, filed October 9, 2002
	42	(1 page)
	43	Fish & Richardson P.C., Request for Continued Examination and Amendment in Reply in U.S.
	43	Serial No. 09/367,950, filed December 10, 2002 (55 pages)
	44	U.S. Examiner Jennifer M. Kim, USPTO Office Action in U.S. Serial No. 09/367,950, mailed March 21, 2003 (9 pages)
	45	Fish & Richardson P.C., Response to Office Action dated March 21, 2003, in U.S. Serial No. 09/367,950, filed June 19, 2003 (9 pages)
		Fish & Richardson P.C., Supplemental Amendment filed July 3, 2003, in U.S. Serial No. 09/367,950
	46	(8 pages)
	47	U.S. Examiner Jennifer M. Kim, Notice of Allowance mailed July 9, 2003, in U.S. Serial No.
	77	09/367,950 (9 pages)
	48	U.S. Examiner Jennifer M. Kim, USPTO Office Action in U.S. Serial No. 09/367,950, mailed
		May 4, 2004 (12 pages) Fish & Richardson P.C., Reply to Office Action dated May 4, 2004, in U.S. Serial No. 09/367,950
	49	filed November 1, 2004 (6 pages)
		U.S. Examiner Jennifer M. Kim, USPTO Office Action in U.S. Serial No. 09/367,950, mailed
	50	March 30, 2005 (14 pages)
		Fish & Richardson P.C., Amendment in Reply to Office Action dated March 30, 2005, in U.S. Serial
	51	No. 09/367,950, filed June 29, 2005 (17 pages)
		U.S. Examiner Jennifer M. Kim, USPTO Office Action in U.S. Serial No. 09/367,950, mailed
	52	September 21, 2005 (15 pages)
		Fish & Richardson P.C., Amendment in Reply to Office Action dated September 21, 2005, in U.S.
	53	Serial No. 09/367,950, filed November 15, 2005 (12 pages)
		U.S. Examiner Jennifer M. Kim, Advisory Action in U.S. Serial No. 09/367,950, mailed December
	54	14, 2005 (3 pages)
	55	Fish & Richardson P.C., Brief on Appeal filed March 3, 2006, in U.S. Serial No. 09/367,950, filed
	,,,	March 3, 2006 (61 pages)

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if no	at in conformance and not considered. Include copy of this form with
next communication to applicant.	and the second s
TI T	Substitute Disclosure Form (PTO-1449)

	Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-0150003	Application No. 10/010,283	
Information Disclosure Statement by Applicant		Applicant Carl-Axel Bauer et al.			
	(Use several si	heets if necessary)	Filing Date November 13, 2001	Group Art Unit 1617	

	Other Documents (include Author, Title, Date, and Place of Publication)			
Examiner	Desig.			
Initial	ID	Document		
	56	U.S. Examiner Jennifer M. Kim, Examiner's Answer in U.S. Serial No. 09/367,950, mailed June 16, 2006 (15 pages)		
	57	Fish & Richardson P.C., Reply Brief on Appeal filed August 14, 2006, in U.S. Serial No. 09/367,950 (15 pages)		
	58	U.S. Examiner Jennifer M. Kim, Communication regarding Appeal Brief in U.S. Serial No.		
*****	59	09/367,950, mailed September 12, 2006 (2 pages) U.S. Examiner Jennifer M. Kim, Notice of Non-Compliant Appeal Brief in U.S. Serial No.		
	39	09/367,950, mailed October 30, 2006 (4 pages)		
	60	Fish & Richardson P.C., Amendment in Reply to Non-Compliant Appeal Brief dated October 30, 2006, in U.S. Serial No. 09/367,950 filed November 28, 2006 (8 pages)		
	61	U.S. Examiner Jennifer M. Kim, Office Communication dated January 24, 2007, in U.S. Serial No. 09/367.950 (2 pages)		
	62	Board of Appeals and Interferences, Order remanding to the Examiner, in U.S. Serial No.		
	02	09/367,950, dated August 28, 2007 (11 pages)		
	63	U.S. Examiner Jennifer M. Kim, Interview Summary mailed October 22, 2007, in U.S. Serial No. 09/367,950 (4 pages)		
	64	Fish & Richardson P.C., Interview Summary Following Board Decision of August 28, 2007, dated November 9, 2007 and re-filed November 21, 2007 in U.S. Serial No. 09/367,950 (13 pages)		
	65	U.S. Examiner Jennifer M. Kim, Office Action in U.S. Serial No. 09/367,950, mailed December 4, 2007 (16 pages)		
	66	Fish & Richardson P.C., Amendment in Reply to Office Action dated December 4, 2007, in U.S. Serial No. 09/367,950 filed June 3, 2008 (37 pages)		
	67	U.S. Examiner Jennifer M. Kim, Final Office Action in U.S. Serial No. 09/367,950, mailed October 6, 2008 (21 pages)		
	68	Fish & Richardson P.C., Amendment in Reply to Final Office Action dated October 6, 2008, in U.S. Serial No. 09/367,950 filed April 3, 2009 (20 pages)		
	69	U.S. Examiner Kendra D. Carter, Office Action in U.S. Serial No. 10/665,240, mailed January 30, 2007 (18 pages)		
	70	Fish & Richardson P.C., Amendment in Reply to Final Office Action dated January 30, 2007, in U.S. Serial No. 10/665,240, filed July 27, 2007 (30 pages)		
	71	U.S. Examiner Kendra D. Carter, Final Office Action in U.S. Serial No. 10/665,240, mailed October 18, 2007 (25 pages)		
	72	Fish & Richardson P.C., Amendment in Reply to Final Office Action dated October 18, 2007 in U.S. Serial No. 10/665,240, filed April 17, 2008 (14 pages)		
		U.S. Examiner Kendra D. Carter, Advisory Action Before the Filing of an Appeal Brief in U.S.		
	73	Serial No. 10/665,240, dated May 5, 2008 (5 pages)		
	74	U.S. Examiner Kendra D. Carter, Final Office Action in U.S. Serial No. 10/665,240, mailed September 19, 2008 (16 pages)		
		Fish & Richardson P.C., Amendment in Reply to Final Office Action dated September 19, 2008, in		
	75	U.S. Serial No. 10/665,240, filed March 18, 2009 (21 pages)		

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with	
next communication to applicant.	